Hengrui Medicine Haitu Popa was approved to go public, and was selected as important medical progress in China in 2021

A few days ago, the Chinese Academy of Medical Sciences released a total of 31 important medical progress in China in 2021 at the Chinese Medical Development Conference. These medical progress comes from the fields of clinical medicine, dental medicine, basic medicine and biology, pharmacy, health, and environment. The results of the research results of Swiss Medicine, "Small molecule human thrilling, genericin receptor excitement, Haiqu Pa Pa ethanlamine tablets" was approved as an important medical progress in China in the field of pharmacy in 2021.

It is reported that important medical progress in China in 2021 focuses on the progress of medical science and technology that has certain academic influence, social influence and promotion of discipline development, improved the practice of "preventing the diagnosis and control", and promotes the potential of the health industry. The classification evaluation method combined with the combination of "diversified measurement indicators" and "multi -subject research and judgment" is incorporated into multi -source data without bias, including the medical research papers published by Chinese researchers in 2021, an authorized international patent, and a domestic domestic production. Drug products and approved domestic innovative medical device products have collected more than 276,000 data as a selection of basic data.

After the research team conducted quantitative analysis, expert evaluation, and comprehensive research and judgment, after forming 77 preparation options, it was recommended by members of the Academic Council of the Academic Consultation Committee of the Chinese Academy of Medical Sciences, reviewing the review committee, and review of the executive committee, and finally produced 31 important progress of the year.

Hengrui Pharmaceutical's independently developed type 1 new medicine sea alcoholamine tablets (product name: Hengqu?) Is a oral non-peptide platelet formation receptor (TPO-R) agonist. Major special support. In June 2021, the State Drug Administration (NMPA) approved the listing of Hengrui Pharmaceutical Haiqu Pa Pa ethanol. (ITP) Treatment of adult patients, as well as the treatment of adult patients for adult patients for adult patients who are used for poor immunosuppressive treatment.

In January 2022, the phase II clinical study of Phase III in the treatment of malignant tumor chemotherapy in the treatment of malignant tumor chemotherapy was approved for clinical trials in the United States. In mid -June of this year, Haiqu Paopa ethanlamine tablets were used to obtain orphan drug qualifications awarded by the American Food and Drug Administration ("FDA") in the United States Food and Drug Administration ("FDA").

As an international pharmaceutical company engaged in the development and promotion of innovation and high -quality drugs, in recent years, Hengrui Pharmaceutical has vigorously promoted technological innovation and internationalization strategies. In 2021, the company's cumulative R & D investment was 6.203 billion yuan, an increase of 24.34%over the previous year. R & D investment accounted for 23.95%of sales revenue, a record high. With this support, Hengrui has been approved to be listed at present, and more than 60 innovative drugs are being developed in clinical development. More than 250 clinical trials were carried out at home and abroad, of which nearly 20 international clinical trials were carried out. In the research and development of innovative drugs, a batch of listed batch, clinical batch, and development of a batch of virtuous cycles were basically formed.

Recently, Hengrui Pharmaceutical's independently developed type 1 new drug SHR8554 injection solution for the treatment of severe pain indications for the symptoms of severe pain indication after abdominal surgery was applied to be accepted by the State Drug Administration.

In December 2021, the evaluation SHR8554 injection liquid was used for the effectiveness and safety of the analgesic of the abdominal surgery (scheme number: SHR8554-301). The study was a main researcher, and 55 centers across the country participated by Professor Chen Xiangdong, Affiliated to the Tongji Medical College of Huazhong University of Science and Technology. The research results show that the SHR8554 injection can effectively treat severe pain after abdominal surgery, significantly improved the subject's satisfaction with analgesic therapy.

It is worth noting that the SHR8554 injection is a new type of new medicine independently developed by Hengrui Pharmaceutical. At present, there are no similar drugs in China.

Responsible editor Ni Liqi

- END -